Abstract
The proto-oncogenes YAP and TAZ have previously gained much attention as downstream effectors of Hippo tumour suppressor signalling. While the regulation of YAP/TAZ by MST/LATS kinases is reasonably well understood, the nature of factors functioning upstream of MST/LATS is yet to be elucidated in detail. A recent paper by Ma and co-workers defines a novel role for leukemia inhibitory factor receptor (LIFR) signalling upstream of the Hippo-YAP pathway in breast cancer metastasis. Moreover, a whole genome in vivo RNA interference screen by Lippmann and colleagues identified LIFR as a breast tumour suppressor. Here, we discuss the implications of these studies for breast cancer research and treatment.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acyltransferases
-
Adaptor Proteins, Signal Transducing / genetics*
-
Breast Neoplasms / genetics*
-
Female
-
Genes, Tumor Suppressor*
-
Hippo Signaling Pathway
-
Humans
-
MAP Kinase Kinase Kinases / metabolism
-
Phosphoproteins / genetics*
-
Protein Serine-Threonine Kinases / genetics*
-
Protein Serine-Threonine Kinases / metabolism
-
RNA Interference
-
Receptors, OSM-LIF / genetics*
-
Signal Transduction / genetics
-
Transcription Factors / genetics
-
YAP-Signaling Proteins
Substances
-
Adaptor Proteins, Signal Transducing
-
Phosphoproteins
-
Receptors, OSM-LIF
-
Transcription Factors
-
YAP-Signaling Proteins
-
YAP1 protein, human
-
Acyltransferases
-
TAFAZZIN protein, human
-
LATS1 protein, human
-
Protein Serine-Threonine Kinases
-
MAP Kinase Kinase Kinases
-
MAP3K10 protein, human